Literature DB >> 8586467

Molecular pathways in the formation of gliomas.

A von Deimling1, D N Louis, O D Wiestler.   

Abstract

The past few years have seen remarkable progress in understanding the molecular genetic basis of glioma formation. Affected oncogenes and tumor suppressor genes have been identified and putative tumor suppressor loci have been mapped. These studies have illustrated distinct molecular pathways for different glial neoplasms. We summarize the findings of an ongoing study initiated to characterize human gliomas on a molecular basis. The data are compiled from 150 astrocytic, oligodendroglial, and mixed gliomas that were assessed for genomic alterations characteristic of these neoplasms, i.e., loss of portions of chromosomes 1p, 9p, 10, 17p, 17q, and 19q, mutations of the p53 tumor suppressor gene, and amplification of the EGF receptor (EGFR) gene. Our findings support the hypothesis that distinct genetic pathways result in the formation of astrocytic and oligodendroglial neoplasms of different malignancy grades, and that glioblastoma multiforme may be subdivided into genetically distinct subsets. Such findings may not only lead to a better understanding of neoplastic transformation in glial cells, but may also have a major impact on clinical neuro-oncology.

Entities:  

Mesh:

Year:  1995        PMID: 8586467     DOI: 10.1002/glia.440150312

Source DB:  PubMed          Journal:  Glia        ISSN: 0894-1491            Impact factor:   7.452


  52 in total

1.  Identification of uncommon chromosomal aberrations in the neuroglioma cell line H4 by spectral karyotyping.

Authors:  D Krex; B Mohr; M Hauses; G Ehninger; H K Schackert; G Schackert
Journal:  J Neurooncol       Date:  2001-04       Impact factor: 4.130

Review 2.  Roles of transforming growth factor-alpha and related molecules in the nervous system.

Authors:  C J Xian; X F Zhou
Journal:  Mol Neurobiol       Date:  1999 Oct-Dec       Impact factor: 5.590

Review 3.  Genetic basis of intramedullary spinal cord tumors and therapeutic implications.

Authors:  A T Parsa; A J Fiore; P C McCormick; J N Bruce
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

Review 4.  "...those left behind." Biology and oncology of invasive glioma cells.

Authors:  M E Berens; A Giese
Journal:  Neoplasia       Date:  1999-08       Impact factor: 5.715

5.  Epidermal growth factor and fibroblast growth factor-2 have different effects on neural progenitors in the adult rat brain.

Authors:  H G Kuhn; J Winkler; G Kempermann; L J Thal; F H Gage
Journal:  J Neurosci       Date:  1997-08-01       Impact factor: 6.167

6.  A unique model system for tumor progression in GBM comprising two developed human neuro-epithelial cell lines with differential transforming potential and coexpressing neuronal and glial markers.

Authors:  Anjali Shiras; Arti Bhosale; Varsha Shepal; Ravi Shukla; V S Baburao; K Prabhakara; Padma Shastry
Journal:  Neoplasia       Date:  2003 Nov-Dec       Impact factor: 5.715

Review 7.  Immunotherapy for malignant gliomas: emphasis on strategies of active specific immunotherapy using autologous dendritic cells.

Authors:  Steven De Vleeschouwer; Stefaan W Van Gool; Frank Van Calenbergh
Journal:  Childs Nerv Syst       Date:  2004-09-28       Impact factor: 1.475

8.  Detection of JC virus DNA sequence and expression of the viral oncoprotein, tumor antigen, in brain of immunocompetent patient with oligoastrocytoma.

Authors:  A Rencic; J Gordon; J Otte; M Curtis; A Kovatich; P Zoltick; K Khalili; D Andrews
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

9.  Prognostic value of loss of heterozygosity around three candidate tumor suppressor genes on chromosome 10q in astrocytomas.

Authors:  Kinya Terada; Takashi Tamiya; Shigeru Daido; Hirokazu Kambara; Hiroaki Tanaka; Yasuhiro Ono; Kengo Matsumoto; Sachio Ito; Mamoru Ouchida; Takashi Ohmoto; Kenji Shimizu
Journal:  J Neurooncol       Date:  2002-06       Impact factor: 4.130

10.  MTH-68/H oncolytic viral treatment in human high-grade gliomas.

Authors:  L K Csatary; G Gosztonyi; J Szeberenyi; Z Fabian; V Liszka; B Bodey; C M Csatary
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.